- Category: Experimental HCV Drugs
- Published on Tuesday, 04 March 2014 16:11
- Written by Keith Alcorn
A 12-week triple combination of direct-acting antivirals developed by AbbVie cured at least 99% of previously untreated people with genotype 1 hepatitis C infection, Rajendar Reddy of the University of Pennsylvania Hospital told the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) in Boston on Tuesday. This is expected to be the first approved interferon- and ribavirin-free combination for genotype 1b, available by the end of 2014.